DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solution

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Persistent Corneal Epithelial Defect

Conditions

Persistent Corneal Epithelial Defect

Trial Timeline

Sep 1, 2009 → —

NCT ID

NCT00988494

About DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solution

DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solution is a phase 2 stage product being developed by Santen Pharmaceutical for Persistent Corneal Epithelial Defect. The current trial status is completed. This product is registered under clinical trial identifier NCT00988494. Target conditions include Persistent Corneal Epithelial Defect.

What happened to similar drugs?

4 of 8 similar drugs in Persistent Corneal Epithelial Defect were approved

Approved (4) Terminated (1) Active (4)

✅Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + PlaceboNovartisApproved

✅RivastigmineNovartisApproved

✅Omalizumab + PlaceboNovartisApproved

✅irbesartan + placeboSanofiApproved

🔄E7777 9 mcg/kgEisaiPhase 3

🔄CertoparinNovartisPhase 3

🔄Omalizumab + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00988494	Phase 2	Completed	Sep 1, 2009	—	Persistent Corneal Epithelial Defect

Competing Products

20 competing products in Persistent Corneal Epithelial Defect

See all competitors

Product	Company	Stage	Hype Score
E7777 9 mcg/kg	Eisai	Phase 3	40
Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E	AstraZeneca	Phase 1	29
AZD0837 + VKA INR 2-3	AstraZeneca	Phase 2	35
AZD0837 + Aspirin	AstraZeneca	Phase 2	35
Montelukast to placebo + Placebo to montelukast	Merck	Pre-clinical	26
Everolimus + Tamoxifen + Letrozole + Medroxyprogesterone Acetate	Novartis	Phase 2	35
Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + Placebo	Novartis	Approved	35
Certoparin	Novartis	Phase 3	40
Omalizumab + Placebo	Novartis	Phase 3	40
Rivastigmine	Novartis	Approved	43
QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 days	Novartis	Phase 2	35
Indacaterol + Placebo to Indacaterol	Novartis	Phase 2	35
Omalizumab + Placebo	Novartis	Approved	43
placebo + iv sildenafil	Pfizer	Phase 3	40
etanercept + placebo	Pfizer	Phase 2	35
Sildenafil	Pfizer	Phase 2	27
irbesartan + placebo	Sanofi	Approved	39
iloprost	Bayer	Pre-clinical	15
IV Remodulin + Placebo	United Therapeutics	Phase 2	24
Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen)	Glaukos	Phase 2	24